You are here

Eli Lilly

Top 10 pharma R&D budgets in 2022

Top 10 pharma R&D budgets in 2022

Fierce Biotech

Bristol Myers Squibb

Flag link:

Eli Lilly to increase investment to $1B into new Irish manufacturing facility — report

Eli Lilly to increase investment to $1B into new Irish manufacturing facility — report

Endpoints

drug manufacturing

Flag link:

Novo's high-dose Rybelsus win tees up regulatory filings—and new rivalries

Novo's high-dose Rybelsus win tees up regulatory filings—and new rivalries

Fierce Pharma

clinical trials

Flag link:

Will Eli Lilly Be a Trillion-Dollar Stock by 2030?

Will Eli Lilly Be a Trillion-Dollar Stock by 2030?

Motley Fool

Flag link:

Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test

Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test

PM Live

Alzheimer's disease

Flag link:

Flare fires up with $123M series B to target transcription factors with 3 Big Pharmas in tow

Flare fires up with $123M series B to target transcription factors with 3 Big Pharmas in tow

Fierce Biotech

Flare Therapeutics

transcription factors

Flag link:

AACR 2023 – Moderna's immunotherapeutic splash

AACR 2023 – Moderna's immunotherapeutic splash

EP Vantage

Moderna Therapeutics

Relay Therapeutics

Vivace Therapeutics

Flag link:

Eli Lilly signs CSO Daniel Skovronsky to $5M non-compete clause

Eli Lilly signs CSO Daniel Skovronsky to $5M non-compete clause

Medical Marketing and Media

Daniel Skovronsky

Flag link:

Three's company: Sanofi follows lead of Lilly and Novo, slashes insulin price by 78% and caps out-of-pocket costs

Three's company: Sanofi follows lead of Lilly and Novo, slashes insulin price by 78% and caps out-of-pocket costs

Endpoints

Flag link:

SEC says Eli Lilly can't avoid requests for more info on diversity efforts, abortion stance

SEC says Eli Lilly can't avoid requests for more info on diversity efforts, abortion stance

Endpoints

Flag link:

Strategy Behind Lowered Insulin Prices: Novo Nordisk and Eli Lilly

Strategy Behind Lowered Insulin Prices: Novo Nordisk and Eli Lilly

BioSpace

Flag link:

Novo Nordisk Will Lower Insulin Prices Up To 75%, Following Eli Lilly

Novo Nordisk Will Lower Insulin Prices Up To 75%, Following Eli Lilly

Forbes

Flag link:

Lilly’s Alzheimer’s struggles continue as preclinical asset fails phase III

Lilly’s Alzheimer’s struggles continue as preclinical asset fails phase III

BioSpace

Alzheimer's disease

clinical trials

Flag link:

Eli Lilly kicks off consumer campaign for diabetes drug Mounjaro

Eli Lilly kicks off consumer campaign for diabetes drug Mounjaro

Medical Marketing and Media

Flag link:

Armed with $60M series A and Lilly's backing, Volastra enters clinic via Amgen cancer med

Armed with $60M series A and Lilly's backing, Volastra enters clinic via Amgen cancer med

Fierce Biotech

Volastra Therapeutics

Flag link:

FDA widens Lilly's Verzenio breast cancer reach, removes test and menopausal status demands

FDA widens Lilly's Verzenio breast cancer reach, removes test and menopausal status demands

Fierce Pharma

Flag link:

Sanders urges Sanofi, Novo Nordisk to be like Eli Lilly in reducing insulin prices

Sanders urges Sanofi, Novo Nordisk to be like Eli Lilly in reducing insulin prices

Fierce Pharma

Flag link:

Eli Lilly licenses non opioid pain med for $40M upfront

Eli Lilly licenses non opioid pain med for $40M upfront

Seeking Alpha

Confo Therapeutics

non-opioid pain treatments

Flag link:

Lilly to cut insulin prices by 70%, cap prices at $35 per month for people with private insurance

Lilly to cut insulin prices by 70%, cap prices at $35 per month for people with private insurance

CNBC

Flag link:

Big-sellers from Merck, Novo and Lilly likely to face Medicare price negotiations: report

Big-sellers from Merck, Novo and Lilly likely to face Medicare price negotiations: report

Fierce Pharma

Boehringer Ingelheim

Flag link:

Pages